Chemoimmunotherapy Is Associated With Tumor Downstaging in Urothelial Cancer
April 12th 2023Neoadjuvant pembrolizumab plus gemcitabine with or without cisplatin led to high rates of downstaging to non–muscle invasive urothelial cancer in patients with muscle-invasive urothelial cancer, meeting the primary end points for both cohorts of the phase 1b/2 HCRN GU14-188 trial.
Read More
Durvalumab Plus Guadecitabine Induces Responses in Checkpoint Inhibitor–Naïve ccRCC
April 10th 2023The combination of durvalumab and guadecitabine generated early signs of clinical activity and tolerability in patients with advanced clear cell renal cell carcinoma, particularly those with no prior exposure to checkpoint inhibitors.
Read More
NCDB Analysis Shows Survival Benefit With Surgery vs Chemoradiation in NSCLC
April 10th 2023Janeesh Sekkath Veedu, MBBS, discusses the need for research comparing outcomes with surgery-based treatment vs CRT and immunotherapy in stage IIIA NSCLC, shares findings from a NCDB analysis, and emphasizes the importance of continuing this research as updated data become available.
Read More
Novel CDK9 Inhibitor Under Investigation in Solid Tumors and NHL
April 5th 2023Miguel Villalona-Calero, MD, discusses the unique mechanism of action of KB-0742 and the rationale and design of a phase 1 trial investigating the safety and efficacy of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.
Read More
Quizartinib May Represent an Additional Therapeutic Option for FLT3-ITD+ AML
April 3rd 2023Mark Levis, MD, PhD, discusses potential changes to the FLT3-ITD-mutated acute myeloid leukemia treatment landscape that may occur if the FDA approves quizartinib, key efficacy and safety data with the agent, and how quizartinib compares with midostaurin.
Read More
Tamibarotene Combinations Under Investigation in Newly Diagnosed AML and MDS
April 3rd 2023Gautam Borthakur, MD, discussed the rationale for targeting RARA-overexpressing AML, the potential efficacy and safety benefits of tamibarotene, and how SELECT AML-1 and SELECT MDS-1 could change the respective treatment landscapes in AML and MDS.
Read More
Applied Molecular Medicine Signals the Future of Personalized, Preventive Cancer Care
April 3rd 2023Andre Goy, MD, discusses advances in the field of oncology that prompted the development of the Hennessy Institute, how early cancer detection can improve patient outcomes, and the importance of employing accessible cancer prevention strategies.
Read More
Obe-cel May Prove a Tolerable Treatment Alternative in Relapsed/Refractory B-ALL
March 28th 2023Sameem Abedin, MD, discusses where CAR T-cell therapy falls in the treatment paradigm for B-cell acute lymphoblastic leukemia, the known safety profile of obe-cel as evidenced in early studies, and how findings from the FELIX trial could change the future management of this disease.
Read More
Research Clarifies Treatment Patterns and Raises New Questions Across GI Cancers
March 23rd 2023Jimmy Hwang, MD, discusses findings supporting the use of immunotherapy in hepatocellular carcinoma and biliary tract cancer, the potential benefits of antibody-drug conjugates in metastatic colorectal cancer, and unmet needs in esophageal squamous cell carcinoma and rectal cancer.
Read More
Newly Defined Breast Cancer Targets Expand TNBC Treatment Options
March 23rd 2023Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.
Read More
Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium
March 18th 2023Eunice Wang, MD, discusses the current standards for classifying and treating unfit patients with AML, treatment considerations for patients unfit for hypomethylating agents, and the potential role of investigational menin inhibitors and immunotherapies in this population.
Read More
PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors
March 17th 2023RBN-2397, a PARP7 inhibitor, was found to be well tolerated and have preliminary antitumor activity as monotherapy in patients with advanced solid tumors, including head and neck squamous cell carcinoma, breast cancer, and squamous cell carcinoma of the lung.
Read More
Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma
March 16th 2023The combination of nivolumab and relatlimab demonstrated clinical benefit with a manageable safety profile in patients with advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression, according to findings from the ongoing phase 1/2a RELATIVITY-020 trial.
Read More
PARP Inhibitors Redefine the Rapidly Changing Ovarian Cancer Landscape
March 15th 2023Erin K. Crane, MD, MPH, describes practice-changing findings from upfront trials with niraparib and olaparib, contextualizes the significance of the manufacturer restrictions of later-line PARP inhibitors for ovarian cancer, and predicts further research efforts in this population.
Read More
Real-World Research Highlights the Importance of Targeted NSCLC Treatment
March 14th 2023Daryl Pritchard, PhD, discussed how recent findings highlight the importance of targeted therapy in advanced lung cancer, areas where the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology could be updated to better encapsulate real-world practice patterns, and the ways in which increased access to molecular testing can help usher in a new era of personalized medicine.
Read More
Jubilee Brown, MD, discusses future considerations for using minimally invasive surgery and PARP inhibitors in ovarian cancer, how immunotherapies have fulfilled an unmet need in cervical cancer, and the importance of leveraging molecular profiling to determine personalized therapeutic strategies in endometrial cancer.
Read More
Ruxolitinib Demonstrates 6-Month Hematocrit Reduction in Polycythemia Vera
March 8th 2023Treatment with ruxolitinib significantly reduced hematocrit levels and the number of yearly phlebotomies in patients with polycythemia vera, according to findings from a prespecified futility analysis of the phase 2b RuxoBEAT trial.
Read More
The combination of savolitinib and durvalumab induced high response rates with a manageable safety profile in patients with metastatic papillary renal cancer with MET-driven disease enrolled to the phase 2 CALYPSO trial, although the trial missed its primary end point of confirmed response rate for the overall study population.
Read More
AR Pathway Inhibitors, ADCs, and IO/TKI Combinations Shape Standard Therapy in GU Cancers
February 24th 2023Chandler Park, MD, MSc, FACP, discusses the evolution of metastatic hormone-sensitive prostate cancer treatment, shifting definitions of metastatic and nonmetastatic castration-resistant prostate cancer, the importance of antibody-drug conjugates in bladder cancer, and the future of biomarkers in renal cell carcinoma.
Read More
Investigational Treatments for Refractory RCC Expand Beyond Immunotherapy
February 23rd 2023Brian I. Rini, MD, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy; the potential role of biomarkers in future targeted treatments; and the need for novel mechanisms such as HIF inhibition to meet the needs of patients who don’t respond to immunotherapy or VEGF TKIs.
Read More
Nab-sirolimus Under Investigation in TSC1/TSC2-Mutated GI Solid Tumors
February 22nd 2023James J. Harding, MD, describes the GI tumors where TSC1 or TSC2 alterations can arise, how the mechanism of action of nab-sirolimus may help fulfill an unmet need in this population, and the importance of using genetic testing to identify patients with mutations in TSC1, TSC2, or other genes to drive targeted treatment.
Read More
Combination Regimens May Expand PARP Inhibitor Efficacy in mCRPC
February 21st 2023Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.
Read More
Multidisciplinary Discussions Move the Needle Toward Innovative Prostate Cancer Care
February 21st 2023Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .
Read More
Tisa-cel Reinfusion Shows Potential as HSCT Bridging Therapy in Pediatric B-ALL
February 19th 2023Second infusion with tisagenlecleucel after prior tisagenlecleucel infusion produced short durations of minimal residual disease-negative responses in children and young adults with B-cell acute lymphoblastic leukemia.
Read More
Atezolizumab/Chemotherapy Trends Toward Improved OS in Urothelial Carcinoma
February 18th 2023First-line atezolizumab plus platinum-based chemotherapy and gemcitabine trended toward improved overall survival compared with placebo plus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.
Read More
Salvage Checkpoint Inhibitors Reduce Peri-ASCT Progression in R/R Hodgkin Lymphoma
February 17th 2023Checkpoint inhibitor–based salvage regimens significantly reduced the likelihood that patients with relapsed/refractory classic Hodgkin lymphoma undergoing transplant would need further salvage therapy vs conventional salvage regimens.
Read More